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COST-EFFECTIVE STRATEGIES FOR THE LONG-TERM MANAGEMENT 
OF DIABETES MELLITUS 
 
KEDAR N. MULPURI 
 
ABSTRACT 	  
 Diabetes mellitus (DM) is a significant public health problem that afflicted 
approximately 29.1 million Americans in 2012 (CDC, 2014). The estimated cost of 
diabetes in the United States in 2012 was $245 billion, including $176 billion in direct 
medical costs and $69 billion in reduced productivity (ADA, 2013a). To reach a 
diagnosis of DM, a clinician generally relies on fasting plasma glucose (FPG), the oral 
glucose tolerance test (OGTT), and/or the Hemoglobin A1c (HbA1c) test (ADA, 2013b). 
Current noninsulin antidiabetic medications include sulfonylureas, GLP-1 analogues, 
DPP-4 inhibitors, biguanides, thiazolidinediones, and SGLT2 inhibitors (Kaiser & 
Oetjen, 2014). Insulin therapies include basal (long-acting insulin analogues), biphasic 
(premixed insulin analogues), prandial (short-acting insulin analogues), and basal bolus 
(a combination of long-acting and short-acting insulin analogues) (Esposito et al., 2012). 
The aim of this study is to review the existing literature on the cost effectiveness of 
diabetes interventions to develop a standardized protocol for early type 2 diabetes care 
that can be delivered through primary care providers.  
 The substantial cost effectiveness of preventative measures, including ad 
campaigns and outreach programs, has already been established (Mendis & Chestnov, 
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2013). Screening for impaired glucose tolerance early and implementing lifestyle and 
pharmacological changes at an early stage are also considered cost effective approaches 
for the long-term management of diabetes mellitus (Gillies et al., 2008). This study 
utilizes six cost effectiveness analyses on both clinical and non-clinical interventions to 
determine a standardized protocol for screening, diagnosing, and treating DM.  
Noninsulin antidiabetic drugs accounted for 78.4% of the 154.4 million 
prescriptions for antidiabetic drugs filled in 2012 (Hampp et al., 2014). Approximately 
half of the noninsulin antidiabetic drugs filled in 2012 was for metformin, whereas 
roughly a quarter of the same category was for sulfonylureas (Hampp et al., 2014). In 
decreasing order, long-acting human analog insulin and fast-acting human analog insulin 
were the most popular insulin variants in the insulin antidiabetic drug market (Hampp et 
al., 2014). Of the noninsulin antidiabetic drugs, the highest proportion of diabetic patients 
who achieved the HbA1C target of <7% were those taking sustained release exenatide (a 
GLP-1 analog) (63.2%) (Esposito et al., 2012). Of the insulin varieties, the highest 
proportion of diabetic patients who achieved the HbA1C target of <7% were those using 
basal bolus insulin (50.2%) (Esposito et al., 2012). While there are some concerns about 
the ability of diabetic patients with chronic kidney disease to clear metformin via renal 
excretion, extensive clinical experience supports its use in diabetic patients with mild to 
moderate renal impairment (Inzucchi et al., 2014).	  
From the cost effectiveness studies, lifestyle modification (i.e., changes in diet 
and exercise) beginning at any age was determined to be a cost-effective approach in 
preventing and treating DM and may be cost saving for adults between the age of 25 to 
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44 (Herman et al., 2005). Screening for DM beginning at age 45 and repeating every 
three years if negative provides the best balance of effectiveness and cost effectiveness 
(Kahn et al., 2010). As a first-line clinical intervention, metformin was established to be 
cost-effective as well in treating DM (but less so compared to lifestyle modification) 
(Herman et al., 2005). Bariatric surgery for diabetics with a BMI greater than or equal to 
35 kg/m2 has also been established as cost effective (Hoerger et al., 2010). Next, in 
considering the ideal frequency of clinical consultations, diabetics with a stable condition 
(assessed as HbA1c ≤7.5%, blood pressure ≤145 mmHg, and total cholesterol ≤201 
mg/dL) can safely be seen by a primary care provider every six months compared to 
every three months with no noticeable decline in long-term health outcomes (Wermeling 
et al., 2014). For cases of T2D that cannot be simply controlled with metformin, 
sulfonylurea has shown that it is overall more cost-effective and effective as a second-
line therapy when compared to DPP-4 inhibitors and GLP-1 analogs (Zhang et al., 2014). 
Cost effectiveness analysis of the long-acting analogue insulin detemir across different 
countries reveals substantially different cost effectiveness for the medication in terms of 
both nominal and purchasing power terms (Home et al., 2014).  
The results of these studies were parsed to establish a long-term clinical protocol 
for primary care providers in screening, diagnosing, and treating type 2 diabetes. Future 
studies should focus on integrating cost effectiveness and comparative effectiveness 
research in implementing even more nuanced clinical decisions through a structured 
protocol. The cost effectiveness of existing and new interventions—both clinical and 
non-clinical in nature—will also need to be continuously assessed to ensure that the 
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measurements incorporate the most accurate set of assumptions on costs and 
effectiveness. 	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INTRODUCTION 
 
Diabetes mellitus (DM) is a significant public health problem worldwide that 
afflicts both developed and developing countries and accounts for a significant portion of 
healthcare costs for any country. Since the discovery of this pathological state, the 
diagnosis and treatment of diabetes have improved a great deal. While there is an ever-
expanding armamentarium of effective interventions in managing diabetes mellitus, it is 
important to also identify the treatments that are most cost-effective so as to reduce the 
burden of healthcare costs attributable to this disease state. This review aims to assimilate 
the current body of research on the pharmacologic approaches to managing diabetes 
mellitus and on the cost-effectiveness analysis of these interventions among others. The 
clinical effectiveness and cost effectiveness of both clinical and non-clinical interventions 
for managing type 2 diabetes (T2D) determined through cost effectiveness studies will be 
utilized in developing a standardized treatment protocol for primary care providers. 
Finally, the predicted effectiveness and cost effectiveness of antidiabetic drugs in the 
pipeline will also be briefly discussed.  
Overview of Diabetes 
In 2012, 29.1 million persons in the United States were estimated to have DM, 
including 21.0 million diagnosed cases and 8.1 million undiagnosed cases (CDC, 2014). 
According to the World Health Organization (WHO), the leading causes of death across 
the world were high blood pressure (13%), tobacco use (9%), high blood glucose (6%), 
physical inactivity (6%), and overweight and obesity (5%) (2009). These risk factors are 
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associated with chronic conditions, such as diabetes, cancer, and heart diseases (WHO, 
2009). These conditions impacted countries across all incomes groups (WHO, 2009).  
In 2012, the estimated cost of diabetes was $245 billion; of this estimate, direct 
medical costs and reduced productivity accounted for $176 billion and $69 billion, 
respectively (ADA, 2013a). Medical expenditures on diabetes can be disaggregated as 
follows: hospital inpatient care (43%), prescription medications used to treat diabetes-
related complications (18%), antidiabetic drugs and supplies (12%), physician office 
visits (9%), and nursing/residential facility stays (8%) (ADA, 2013a). The average annual 
medical expenditures for a patient diagnosed with diabetes totaled $13,700 in 2012, of 
which diabetes accounted for $7,900 (ADA, 2013a). Those with a diabetes diagnosis 
incurred about 2.3 times the medical expenditures as those without one (ADA, 2013a). 
A successful treatment protocol for the long-term management of diabetes 
requires a multifaceted approach in addition to traditional clinical interventions, including 
group counseling programs, self-management education, and lifestyle modification 
(ADA, 2013b). The American Diabetes Association (ADA) strives to identify and assess 
the validity of published studies in order to develop a standard of care for the treatment of 
diabetes mellitus (ADA, 2013b). Of notable interest to the ADA is the cost-effectiveness 
of clinical recommendations for treating DM, including screening, diagnostic exams, and 
treatment regimens (2013b). The ADA’s Professional Practice Committee releases an 
annual update of their guidelines for the standard of care (2013b). Given the numerous 
therapeutics for treating DM that are currently on the market or in the pipeline, it is 
important to continuously assess the cost-effectiveness of these therapeutics in order to 
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assist in the decision-making process for the benefit of physicians, patients, and payers. A 
variety of interventions—both clinical and non-clinical—will be analyzed through cost 
effectiveness studies to determine which ones are most desirable for controlling blood 
glucose levels.  
 Diabetes mellitus describes syndromes associated with dysfunction in the control 
of blood glucose levels (ADA, 2013b). The ADA currently recognizes four 
classifications for DM: type 1 diabetes, type 2 diabetes, other specific types of diabetes, 
and gestational diabetes mellitus (ADA, 2013b). Type 1 diabetes is associated with the 
destruction of pancreatic beta cells, which means that the pancreas has virtually no way 
of creating endogenous insulin (ADA, 2013b). On the other hand, type 2 diabetes is 
associated with both insulin resistance and a gradual decline in the pancreas’s ability to 
release insulin with bidirectional exacerbation (ADA, 2013b). In some situations, it is 
difficult to clinically discern whether a patient has type 1 diabetes or type 2 diabetes 
(ADA, 2013b).  
To reach a diagnosis of DM, a clinician generally relies on the fasting plasma 
glucose (FPG) or the oral glucose tolerance test (OGTT), the latter of which requires a 2-
hour reading following the ingestion of 75 grams of glucose (ADA, 2013b). An A1C test 
is also utilized in clinical practice because it is more convenient albeit with a lower 
sensitivity compared to the other tests (ADA, 2013b). The diagnosis of diabetes requires 
A1C ≥6.5%, FPG ≥126 mg/dL, 2-hour plasma glucose ≥200 mg/dl with OGTT, or 
random plasma glucose ≥200 mg/dL (ADA, 2013b). Controlling blood glucose levels 
(glycemic control) within an individualized optimal range is the focus of most clinical 
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interventions for type 2 diabetes (ADA, 2013b). Because of frequently associated 
cardiovascular risk factors and comorbidities, controlling blood glucose levels within an 
acceptable range is not necessarily a guarantee of higher quality of life or expected life 
years, which are the effectiveness measures employed in cost-effectiveness analysis.  
Biochemical Approaches of Noninsulin Antidiabetic Drugs 
 The broadest categorizations of drugs for treating type 2 diabetes include those 
that act on pancreatic beta cells and those that operate by other means (Kaiser & Oetjen, 
2014). Sulfonylureas, GLP-1 analogues, DPP-4 inhibitors, biguanides, 
thiazolidinediones, and SGLT2 inhibitors are some of the noninsulin antidiabetic drugs 
that work to modulate blood glucose levels by utilizing various biochemical strategies 
independent of insulin stimulation or provision (Kaiser & Oetjen, 2014).  
Sulfonylureas inhibit ATP-dependent potassium channels, which depolarizes the 
cell membrane and allows an influx of calcium through voltage-dependent L-type 
calcium channels (Kaiser & Oetjen, 2014); this has the effect of stimulating insulin 
release in pancreatic beta cells, which results not only in lower blood sugar levels but also 
weight gain (Kaiser & Oetjen, 2014). Also of significance is the greater incidence of 
cardiac events with the use of glibenclamide (glyburide in North America)—a 
sulfonylurea (Kaiser & Oetjen, 2014). 
 Glucagon-like peptide-1 (GLP-1) is another insulin secretagogue (activates 
insulin secretion from beta cells) that is released from intestinal L-cells after eating a 
meal (Kaiser & Oetjen, 2014). In natural form, GLP-1 has a very short half-life (2 
minutes) once it is cleaved by dipetidylpeptidase 4 (DPP-4) (Kaiser & Oetjen, 2014). 
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Thus administering GLP-1 alone will likely not provide prolonged stimulation of insulin 
secretion (Kaiser & Oetjen, 2014). Instead, GLP-1 analogues (e.g., exanatide and 
liraglutide) were developed resistant to cleavage and degradation to increase the half-life 
of the compounds in the bloodstream when injected subcutaneously (Kaiser & Oetjen, 
2014). DPP-4 inhibitors (including sitagliptin, vildagliptin, and saxagliptin) work by 
inhibiting DPP-4 from cleaving endogenous GLP-1, which boosts its levels and allows it 
to act in stimulating beta cells (Kaiser & Oetjen, 2014). GLP-1 analogues have been 
associated with increased activity and greater mass in beta cells (Kaiser & Oetjen, 2014). 
More importantly, since GLP-1 analogues and DPP-4 inhibitors only act in the presence 
of elevated blood glucose levels, the risk of a patient suffering from hypoglycemia as a 
result of their use is low (Kaiser & Oetjen, 2014). Unfortunately, Kaiser and Oetjen note 
that dysfunction of the pancreas, including pancreatitis, acinar cell death, and dysplasia, 
have been identified as side effects of GLP-1 analogues in rodent and animal studies 
(Kaiser & Oetjen, 2014).  
 Biguanides, including metformin, have held a prominent position in the 
antidiabetic drug market (Kaiser & Oetjen, 2014). Metformin acts by inhibiting 
gluconeogenesis in the liver, which helps in lowering blood glucose levels (Kaiser & 
Oetjen, 2014). Surprisingly given its immense popularity, the mechanism of action for 
metformin has only recently been elucidated (Kaiser and Oetjen, 2014; Madiraju et al., 
2014). Metformin selectively inhibits the mitochondrial isoform of glycerophosphate 
dehydrogenase, which ultimately increases the cytosolic NADH-NAD ratio and restrains 
the conversion of lactate to pyruvate—an important precursor of gluconeogenesis 
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(Madiraju et al., 2014). Other proposed but less validated mechanisms include inhibition 
of complex I of the mitochondrial transport chain, which causes a reduction of energy 
stores (higher ADP/ATP and AMP/ATP ratios) resulting in AMP-dependent kinase 
activation (Kaiser & Oetjen, 2014). Several other theories involving AMP-dependent 
kinase and other signaling enzymes that may act to reduce gluconeogenesis in the liver 
have also been proposed (Kaiser & Oetjen, 2014). In any case, metformin remains an 
effective tool for managing blood glucose levels (Kaiser & Oetjen, 2014). Some studies 
even suggest metformin has protective effects, including lower mortality rates and 
reduced risk of cancer and CVD (Kaiser & Oetjen, 2014). It is also important to note that 
metformin is weight neutral, which should mean that diabetic patients who are obese can 
potentially benefit from it (Kaiser & Oetjen, 2014). 
 The mechanisms of action for thiazolidinediones (TZD), including rosiglitazone 
and pioglitazone, are complex (Kaiser & Oetjen, 2014). They not only improve the 
sensitivity of skeletal muscle and liver to insulin but also inhibit gluconeogenesis in the 
liver and promotes anti-inflammatory responses in some organs (Kaiser & Oetjen, 2014). 
Unfortunately the side effect profile of TZD drugs make them much less attractive as 
treatment options: commonly cited adverse effects include fluid retention due to 
abnormal sodium/water balance following kidney reabsorption, long bone fractures, and 
weight gain likely are contraindications to many patients receiving TZD treatment 
(Kaiser & Oetjen, 2014). This could potentially be problematic for patients with chronic 
kidney disease, osteoporosis, and obesity. TZD drugs generally act as agonists for 
PPARγ, a nuclear receptor associated with retinoid X receptors (Kaiser & Oetjen, 2014). 
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Regulatory process for PPARγ activity include phosphorylation, acetylation, 
sumoylation, and ubiquitination (Kaiser & Oetjen, 2014). As previously noted, one of 
challenges facing the use of TZD drugs in clinical practice is the potentially serious side 
effect profile (Kaiser & Oetjen, 2014); recent research on TZD drugs has focused on 
more selective modulation of PPAR (Kaiser & Oetjen, 2014). In addition, potential dual 
PPARγ/α agonists have been explored to benefit from the decrease of blood glucose 
levels through PPARγ agonists and the decrease of lipid levels through PPARα (Kaiser & 
Oetjen, 2014).  
 Finally, another important current class of noninsulin antidiabetic drugs is the 
SGLT2 inhibitors, such as dapagliflozin (Kaiser & Oetjen, 2014). The sodium-glucose 
transporter 2 (SGLT2) is located in the proximal tubule of the kidney (Kaiser & Oetjen, 
2014). When SGLT2 (a low-affinity, high-capacity glucose transporter) is inhibited, 
glucose reabsorption in the kidney is impeded, resulting in lower blood glucose levels 
(Kaiser & Oetjen, 2014). It should be noted that hypoglycemia is not a concern because 
SGLT1 (a high-affinity, low-capacity transporter) is still free to reabsorb glucose once 
the filtrate reaches SGLT1-rich areas in more distal parts of the kidney and the mode of 
action is independent of insulin (Kaiser & Oetjen, 2014). For convenience, a schematic 
that depicts the site of action for the described classes of noninsulin antidiabetic drugs is 
shown in Figure 1 below (Kaiser & Oetjen, 2014).  
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Figure 1: Mechanisms of action for existing and experimental antidiabetic drugs. 
Among other strategies, antidiabetic drugs primarily seek to reduce glucose release from 
the liver, decrease resportion of glucose in the kidneys, and amplify the secretion of 
insulin. Adapted from Kaiser and Oetjen, 2014. 
Biochemical Approaches of Experimental Noninsulin Antidiabetic Drugs 
 Experimental approaches to treating DM have included the following: G-protein 
coupled receptor/free fatty acid receptor 1 (GPR40/FFAR1) activators, glucokinase 
activators, glucagon-receptor blockers, 11β-hydroxysteroid dehydrogenase 1 (11β-HSD 
1) inhibitors, IL-1β neutralizing antibodies, and recombinant TNF-α receptor 2 (Kaiser & 
Oetjen, 2014). The mechanisms of action for these therapies are also shown in Figure 1 
above (Kaiser & Oetjen, 2014). The cost effectiveness of these therapies is impossible to 
predict because all of them are novel approaches to targeting modulators of blood glucose 
levels without any broad consensus of their effectiveness and, furthermore, do not have 
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any established cost data for estimating cost assumptions. The ones most similar to 
existing therapeutics are glucagon-receptor blockers (Kaiser & Oetjen, 2014); while 
glucagon-receptor blockers block glucagon receptors in order to prevent glucagon from 
stimulating gluconeogenesis and increasing blood glucose levels, GLP-1 analogues and 
DPP-4 inhibitors inhibit glucagon secretion (Kaiser & Oetjen, 2014). Glucagon-receptor 
blockers and glucagon-secretion inhibitors are essentially different approaches with the 
same overall goal of preventing glucagon from modulating blood glucose levels (Kaiser 
& Oetjen, 2014). Therefore, the effectiveness of these approaches in lowering blood 
glucose levels are likely comparable to each other, and the use of these therapeutics in 
combination might even offer synergistic effects.  
Effectiveness of Antidiabetic Therapies in Achieving HbA1c Targets 
 Esposito et al. assessed the effectiveness of the following eight drug classes 
utilized in the treatment of type 2 diabetes in reducing Hemoglobin A1C (HbA1C) levels 
to <7%: metformin, sulphonylureas, α-glucosidase inhibitors, thiazolidinediones, 
glinides, DPP-4 inhibitors, GLP-1 analogues, and insulin analogues (2012). The authors 
conducted a systematic review of randomized controlled trials that met rigorous criteria 
for selection (Esposito et al., 2012). The goal of the study was to track the proportion of 
patients with Hemoglobin A1C levels below <7% (Esposito et al., 2012). According to 
the ADA, the optimal HbA1c level is under 7% for non-pregnant adults with type 2 
diabetes, so the ADA recommends that devising or revising a treatment regiment for a 
type 2 diabetic patient should primarily focus on attaining this outcome if it can be 
realistically and safely achieved (as cited in Esposito et al., 2012). In its 2009 estimate, 
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the National Committee for Quality Assurance reported that about 40% of diabetic 
patients (including type 1 and type 2) achieved HbA1c <7% in 2009 (as cited in Esposito 
et al., 2012). 
The authors were able to conduct a meta-analysis on 218 randomized controlled 
trials published between 1994 and 2011 that met their inclusion criteria (Esposito et al., 
2012). These study designs included parallel group, crossover, double-blind, triple-blind, 
single-blind, and open-label structures (Esposito et al., 2012). In addition to mean 
baseline HbA1C values, the authors also included age, gender, treatment category, trial 
duration, year of publication, concomitant drug use, duration of diabetes, and their 
interactions into their meta-regression model (Esposito et al., 2012). In total, the sample 
included 78,945 patients with a mean age range of 50.2 to 62.7 years, trial duration range 
of 12 to 134 weeks, and mean baseline HbA1c range of 7.2 to 11.7% (Esposito et al., 
2012).  
The drug classes reported were further divided into 12 classes from 8 classes to 
account for the sub-categorization of insulin analogues and GLP-1 analogues (Esposito et 
al., 2012). Insulin treatment programs were divided into the basal (long-acting insulin 
analogues), biphasic (premixed insulin analogues), prandial (short-acting insulin 
analogues), and basal bolus (a combination of long-acting and short-acting insulin) 
classes (Esposito et al., 2012). GLP-1 analogues were divided into daily (exenatide and 
liraglutide) and weekly (exantide long-acting release) classes (Esposito et al., 2012). The 
regression results are displayed in Table 1 below (Esposito et al., 2012). 
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Table 1: Changes in HbA1C levels divided by antidiabetic drug class. The table 
includes the outcomes of 342 arms. Adapted from Esposito et al., 2012. 
 
 
 As shown in Table 1, the percentage of patients who reached the HbA1C target of 
<7% was as high as 63.2% (CI 54.1-71.5) for exenatide long-acting release and 25.9% 
(CI 18.5-34.9) for α-glucosidase inhibitors (Esposito et al., 2012). Of the insulin 
therapies, the basal bolus class program excelled with 50.2% (CI 43.0-57.0) of diabetic 
patients reporting HbA1c <7%; in decreasing order, the others included the basal class 
with 38.9% (CI 35.7-42.2) of users reporting HbA1c <7%, the prandial class with 36.3% 
(CI 26.3-47.7), and the biphasic class with 34.4% (CI 31.1-37.9) (Esposito et al., 2012). 
Amongst all GLP-1 agonists, including exenatide long-acting release, 45.7% (42.2-49.2) 
of diabetes patients reported HbA1c <7% (Esposito et al., 2012). In decreasing order, the 
percentage of diabetic patients reporting HbA1c <7% for all noninsulin antidiabetic drugs 
were as follows: sulphonylureas (48.2%), GLP-1 agonists (45.7%), metformin (42.0%), 
glinides (39.1%), DPP-4 inhibitors (39.0%), thiazolidinediones (33.2%), and α-
glucosidase inhibitors (25.9%) (Esposito et al., 2012).  
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Also shown in Table 1 are mean changes from HbA1c baseline; diabetic patients 
taking glinides saw the smallest decrease in HbA1c levels (-0.64%) and those taking 
biphasic insulin saw the greatest decrease in HbA1c levels (-1.91%) (Esposito et al., 
2012). The authors also grouped the patients into different tiers of baseline HbA1c levels 
to see how much noninsulin and insulin antidiabetic drugs contributed to drops in HbA1c 
levels in all tiers (Esposito et al., 2012). The results for both are shown in Figure 2 and 
Figure 3, respectively (Esposito et al., 2012). 
 
Figure 2: Changes in HbA1c levels from baseline HbA1c for all noninsulin drugs. 
The white columns represent the proportion of the tier reaching the <7% HbA1c target 
and the black columns represent the mean decrease in HbA1c levels weighted by number 
of patients. Adapted from Esposito et al., 2012. 
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Figure 3: Changes in HbA1c levels from baseline HbA1c for all insulin drugs. The 
white columns represent the proportion of the tier reaching the <7% HbA1c target and the 
black columns represent the mean decrease in HbA1c levels weighted by number of 
patients. Adapted from Esposito et al., 2012. 
 As shown in Figure 2, noninsulin drugs contribute to progressive declines in 
HbA1c levels as one moves from lower to higher tiers of HbA1c with the exception of 
the baseline >10.0% HbA1c tier (Esposito et al., 2012). In Figure 3, insulin drugs 
demonstrate much more profound declines in HbA1c when scanning from lower HbA1c 
baseline levels to a higher ones (Esposito et al., 2012). It appears that insulin-based 
treatments administered to diabetic patients with higher baseline HbA1c levels are more 
effective than noninsulin treatments at achieving decreases in HbA1c, especially below 
<7% (Esposito et al., 2012). While metformin is commonly prescribed as a monotherapy 
in the earlier stages of type 2 diabetes, disease progression often means more therapeutics 
have to be added to the treatment regimen to control HbA1c (Esposito et al., 2012).  
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Esposito et al. acknowledge the large amount of interstudy heterogeneity with 
heterogeneity greater than 80% for all drug classes (2012). This was the primary 
reasoning for including variables (first-time drug user, gender, mean age, year of 
publication, trial duration, and concomitant drug use) into the regression to try to explain 
some of the heterogeneity (Esposito et al., 2012). The authors found that none of these 
factors significantly explained the interstudy heterogeneity observed in the meta-
regression, except for HbA1c baseline levels (Esposito et al., 2012). Esposito et al., 
however, argue that the heterogeneity amongst the randomized controlled trials were 
addressed with random effects in the regression model (2012). To conclude, the authors 
suggest that the tier of baseline HbA1c levels be taken into strong consideration when 
determining the optimal treatment regimen because there is significant variation in 
efficacy both between and within noninsulin and insulin antidiabetic drug classes at each 
of the baseline HbA1c tiers (Esposito et al., 2012).  
Usage Rates of Antidiabetic Drugs 
 In 2012, roughly 18.8 million U.S. adults filled their antidiabetic drug (ADDs) 
prescriptions at retail pharmacies (Hampp et al., 2014). Given that 13.2 million U.S. 
adults filled antidiabetic drug prescriptions in 2003, this latest figure represents a 42.9% 
increase (Hampp et al., 2014). In other terms, 81.3 per 1,000 adults filled prescriptions 
for ADDs in 2012 compared to 63.1 per 1,000 adults in 2003 (representing an increase of 
28.9%) (Hampp et al., 2014). Of these consumers in 2012, 86.7% used noninsulin 
antidiabetic drugs (NIADDs) and 27.1% used insulin antidiabetic drugs (Hampp et al., 
2014). Overall, the use of noninsulin diabetic drugs increased by 36.2% in 2012 
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compared to 2003 (Hampp et al., 2014). The usage rates for the remaining antidiabetic 
drugs are shown in Figure 4 (Hampp et al., 2014).  
 
Figure 4: Patterns in the filling of antidiabetic drug prescriptions at U.S. retail 
pharmacies from 2003 – 2012. A:  Noninsulin antidiabetic drug prescriptions. B: New 
entrants to the diabetes drug market. Adapted from Hampp et al., 2014. 
As shown in Panel A of Figure 4, the use of biguanides (such as metformin) 
increased to 60.4 million by 2012 (a 97.0% increase compared to 2003) (Hampp et al., 
2014). While the usage of sulfonylureas remains stagnant in absolute terms, its share 
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amongst all NIADDs dropped from 36.3% in 2003 to 26.7% in 2012 (Hampp et al., 
2014). During the same timeframe, thiazolidinediones also saw diminished usage with a 
decrease of 64.0% amongst its peers (Hampp et al., 2014).  
As one can see in Panel B of Figure 4, sitagliptin, a DPP-4 inhibitor, is the fastest 
growing antidiabetic drug prescription among the new entrants to the market with an 
astounding increase in market share of 10.5 million prescriptions between 2003 and 2012 
(Hampp et al., 2014). Other notable mentions that are increasing its share of the 
antidiabetic drug market amongst the new entrants are saxagliptin and liraglutide (Hampp 
et al., 2014). Originally one of the growing products in the same cohort, immediate-
release exenatide, a GLP-1 analog labeled as Byetta by Bristol-Myers Squibb, appears to 
be losing its popularity in utilization amongst physicians in comparison to the other 
newly minted peers (Hampp et al., 2014); its use reached its peak in 2008 with 2.5 
million prescriptions (Hampp et al., 2014). This sharp decline likely can be attributed to 
the introduction of liraglutide, which gained popularity in utilization amongst GLP-1 
analogs (Hampp et al., 2014). In January 2012, however, a once-weekly extended-release 
exenatide formulation was approved by the U.S. Food and Drug Administration (FDA) 
and marketed as Bydureon by Bristol-Myers Squibb (Hampp et al., 2014); this 
formulation would represent 20.3% of all exenatide prescriptions filled at U.S. retail 
pharmacies in 2012 (Hampp et al., 2014).  
As of 2012, 154.5 million prescriptions for antidiabetic drugs were filled with 
noninsulin varieties accounting for 78.4% of the total (Hampp et al., 2014). 
Unsurprisingly, single-ingredient metformin accounted for roughly one out of every two 
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prescriptions for noninsulin antidiabetic drugs (Hampp et al., 2014). It was used by a 
staggering 11.8 million of the 16.3 million noninsulin antidiabetic drug users (Hampp et 
al., 2014). Sulfonylureas, including glipizide, glimepiride, and glyburide, accounted for 
more than a quarter of all NIADDs prescribed (Hampp et al., 2014). Also of importance 
was how DPP-4 inhibitors were pre-eminent in the utilization of newly introduced 
incretin-based drugs (Hampp et al., 2014).  
5.1 million patients received the 33.4 million insulin prescriptions that were filled 
in 2012 (Hampp et al., 2014). The most popular preparations in the insulin market in 
sequential order were long-acting human analog insulin (e.g., insulin glargine) and fast-
acting human analog insulin (e.g., insulin aspart and insulin lispro) (Hampp et al., 2014).  
In looking at utilization rates, it is important to consider what combinations of 
therapies are being used (Hampp et al., 2014). In 2012, metformin use as a monotherapy 
accounted for 44% of prescriptions filled in U.S. retail pharmacies. Its concomitant use 
with other prescriptions was as follows: sulfonylurea (22.1%), DPP-4 inhibitors (22.0%), 
and long-acting insulin (9.7%) (Hampp et al., 2014). In the reverse perspective, between 
51.9% (GLP-1 analogs) and 66.6% (thiazolidinediones) of noninsulin antidiabetic drug 
use was in conjunction with metformin (Hampp et al., 2014). Approximately one-third of 
long-acting insulin use occurred in conjunction with fast-acting insulin use; conversely, 
two thirds of fast-acting insulin was utilized in conjunction with long-acting insulin 
(Hampp et al., 2014). It is clear from these data that metformin and long-acting insulin 
are the primary options of the noninsulin antidiabetic drugs and insulin antidiabetic 
drugs, respectively (Hampp et al., 2014). As such, a clinician likely utilizes these two 
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therapies as the benchmark for evaluating the clinical effectiveness of proposed diabetes 
treatment regimens. 
From analyzing these trends, Hampp et al. describe the ease of use of some of 
these products as the force behind their growth in market share (2014). For example, 
liraglutide, a GLP-1 analog, requires one injection daily compared to immediate release 
exanatide, which requires two daily injections (Hampp et al., 2014). This fact could 
explain some of the decline seen in exanatide’s share of the market from 2003 to 2012 
(Hampp et al., 2014). It is also notable that the extended-release exanatide required only 
one weekly injection and thus gained instant popularity when it was released in 2012, 
which at least helped to maintain the stability of exanatide prescriptions in nominal terms 
(Hampp et al., 2014). Also mentioned is the growth of DPP-4 inhibitor use likely 
propelled by their availability as oral tablets (Hampp et al., 2014).  
Hampp et al. also noted that 6.7% of noninsulin antidiabetic drug prescriptions 
were written for combination products, especially combinations that included metformin 
in conjunction with sitagliptin and glyburide (2014). Combination therapies of metformin 
with DPP-4 inhibitors were also a significant part of all DPP-4 inhibitor-containing 
therapies (Hampp et al., 2014).  Also shown was that one-half to two-thirds of 
sulfonylurea, DPP-4 inhibitor, thiazolidinedione, and GLP-1 analog prescriptions were in 
conjunction with metformin prescriptions (Hampp et al., 2014). Hampp et al. found this 
trend peculiar because clinical guidelines generally recommend continuing metformin 
use in addition to noninsulin antidiabetic drugs unless its use is contraindicated or not 
well-tolerated by the patient (2014). Finally, the authors acknowledge that 
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rosiglitazone—a thiazolidinedione—had an abrupt decline when the association between 
cardiovascular events and rosiglitazone was revealed (as cited in Hampp et al., 2014); 
rosiglitazone was heavily restricted by the FDA in May 2011 with few exceptions (as 
cited in Hampp et al., 2014). Pioglitazone-containing medications would then supplant 
rosiglitazone as the leading thiazolidinedione on the market with 6.8 million prescriptions 
filled at U.S. retail pharmacies in 2012 (Hampp et al., 2014). In November 2013, 
however, the FDA lifted the ban on rosiglitazone, which may lead to increased utilization 
of rosiglitazone in the future (as cited in Hampp et al., 2014). 
Complications Arising from Comorbidities 
 Metformin’s pre-eminence as the primary option for treating type 2 diabetes can 
be attributed to its low cost, safety profile, and prospective cardiovascular benefits 
(Inzucchi et al., 2014). Metformin use, however, can be problematic for patients with 
cardiovascular, renal, hepatic, and pulmonary diseases (Kaiser & Oetjen, 2014). In most 
cases, metformin will suffice for a patient with few comorbidities, but diabetic patients 
with kidney disease, in theory, are believed to struggle to clear metformin via renal 
excretion, which may lead to the eventual accumulation of lactate (resulting in lactic 
acidosis) (Inzucchi et al., 2014). Of the 21 million patients estimated to have type 2 
diabetes, roughly 12% of them are also estimated to have impaired kidney function 
concurrently (as cited in Inzucchi et al., 2014). While drug labeling warns of metformin-
associated lactic acidosis based on moderate pharmacokinetic research, the incidence of 
lactic acidosis in patients with metformin is estimated to be 1 per 23,000 to 30,00 person-
years, which is even lower than the estimate of 1 per 18,000 to 21,000 person-years for 
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patients using other medications (as cited in Inzucchi et al., 2014). Inzucchi et al. sought 
to review existing literature studies to discover the true incidence of metformin-
associated lactic acidosis in clinical studies with special attention given to those with 
chronic kidney disease to see whether the results warrant a change in clinical guidelines 
(2014).  
 It is believed that biguanides, including metformin, inhibit the mitochondrial 
respiratory chain, which limits aerobic respiration and thus energy production (Inzucchi 
et al., 2014). This should favor lactate synthesis and lead to elevated levels of lactate in 
the bloodstream (Inzucchi et al., 2014). Inzucchi et al., however, found in their review 
that the levels of lactate circulating in the bloodstream for diabetic patients taking 
metformin were fairly normal for each patient, including for those patients also having 
chronic kidney disease (2014). While metformin levels in the bloodstream of diabetic 
patients with chronic kidney disease are elevated compared to those without it, the levels 
of lactate in the bloodstream do not increase significantly when metformin is added to the 
treatment regimen (Inzucchi et al., 2014). In most cases, the clinical guidelines warning 
of metformin use in diabetic patients with chronic kidney disease are ignored (as cited in 
Inzucchi et al., 2014); even when metformin is prescribed for this population, its use is 
not associated with any additional occurrence of adverse effects and may even be 
associated with additional clinical benefits for this subpopulation compared to the overall 
population of diabetic patients (as cited in Inzucchi et al., 2014).  
 The fear of metformin use in diabetic patients with chronic kidney disease likely 
originates from the discontinuation of phenformin—another biguanide—almost 40 years 
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ago (as cited in Inzucchi et al., 2014). In the case of phenformin, the drug was associated 
with significant increased risk of lactic acidosis, but its metabolism pathway is much 
different from that of metformin (as cited in Inzucchi et al., 2014). While metformin is 
cleared entirely by the kidney (with a half-life of 6.5 hours), phenformin metabolism 
undergoes both hepatic and renal clearance processes, resulting in a larger half-life of 7-
15 hours compared to metformin (as cited in Inzucchi et al., 2014). Phenformin’s 
lipophilic tendency compared to metformin also accounts for its affinity to mitochondrial 
membranes, which could result in the inhibition of aerobic respiration and potentially 
higher lactate levels (Inzucchi et al., 2014). In comparison, metformin is not 
demonstrably associated with lactate release in the muscle and lactate oxidation seen with 
phenformin (Inzucchi et al., 2014). In short, the evidence against metformin use in 
patients with chronic kidney disease in order to avoid the risk of lactic acidosis is dubious 
at best, and the restrictions on metformin use in this subgroup based on scant clinical 
evidence of its potential risks could hinder potential clinical benefits and cost savings.  
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PUBLISHED STUDIES 
 
According to Hicks and Jacobs, “economic evaluation analysis involves the 
quantification of changes in health resource use and outcomes due to the introduction of 
new interventions” (2014). The most cost-effective strategies for reducing costs on 
cardiovascular disease and diabetes seem to be preventative measures taken before the 
incidence of disease, including ad campaigns and outreach programs designed to 
discourage tobacco use, alcohol use, unhealthy eating, and sedentary lifestyles (Mendis & 
Chestnov, 2013). Screening for impaired glucose tolerance in those at risk for diabetes 
and implementing lifestyle and pharmacological modifications at an early stage is also 
considered a cost-effective measure in reducing the incidence of diabetes (Gillies et al., 
2008). To further explore the cost effectiveness of both clinical and non-clinical 
interventions, a few choice studies were selected for examination. These cost 
effectiveness studies include both long-standing and recently published works.  
Cost-Effectiveness of Diabetes Screening 
Kahn et al. prepared a sample of 325,000 people from the US population who 
were 30 years of age without a current diabetes diagnosis (2010). The authors then 
utilized the Archimedes model to compare eight proposed approaches to screening and 
compared these results to the no-screening approach (Kahn et al., 2010). Each of these 
strategies had a proposed time to begin screening and a proposed frequency of screening 
(the latter of which is expressed in parentheses): 30 years (every 3 years), 45 years (every 
year), 45 years (every 3 years), 45 years (every 5 years), 60 years (every 3 years), 
hypertension diagnosis (every year), hypertension diagnosis (every 5 years), and 
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maximum screening (Kahn et al., 2010). The simulation, which was necessitated by the 
lack of clinical trial data, then accounted for the expected diabetes treatment upon 
detection and included the incidence of diabetes-related complications (myocardial 
infarction, stroke, and microvascular disease) in order to determine the impact on quality 
of life, life expectancy, and costs (Kahn et al., 2010). The comparisons of these eight 
strategies to the null strategy can be found in Figure 5 and Figure 6 (Kahn et al., 2010).  
 
Figure 5: QALYs added for each of the proposed screening strategies compared to 
the null strategy. The error bars represent the 95% confidence interval for the QALYs 
added per 1,000 people after 50 years of follow-up based on the screening strategy 
compared to the null strategy. Adapted from Kahn et al., 2010. 
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Figure 6: Cost per QALY (US$/QALY) for each of the proposed screening strategies 
compared to the null strategy. The error bars represent the 95% confidence interval for 
the cost per QALY (undiscounted) after 50 years of follow-up based on the screening 
strategy compared to the null strategy. Adapted from Kahn et al., 2010. 
 
Figure 5 reveals that maximum screening (i.e., screening starting at age 30 and 
repeated every 6 months until age 75) added the most QALYs per 1,000 people after a 50 
year follow-up period as one would expect (Kahn et al., 2010). In a society with 
unlimited healthcare resources, this strategy could be pursued, but in reality, this 
approach is simply not practical. Screening at age 60 repeated every 3 years, on the other 
hand, added the least number of QALYs of the eight proposed strategies (Kahn et al., 
2010). This result suggests that screening at 60 years is likely too late to substantially 
alter the health outcome of the patient. Figure 6 reveals the cost per QALY for each of 
the strategies in comparison to the control (i.e., the null strategy of no screening) (Kahn et 
al., 2010). The results reveal the impracticality of maximum screening with an 
incremental cost effectiveness ratio of $40,778/QALY (Kahn et al., 2010). The strategy 
for screening at hypertension diagnosis repeated every year (i.e., once blood pressure 
exceeds 140/90 mmHg and repeated every year thereafter) had the most attractive 
	  25 
incremental cost effectiveness ratio ($6,287/QALY) (Kahn et al., 2010). Unfortunately, 
this strategy only added 78 QALYs per 1,000 people, which is significantly lower than 
five of the proposed strategies (Kahn et al., 2010). Kahn et al. instead were drawn to the 
strategies of screening at age 30 or age 45 and repeating every 3-5 years thereafter 
because these strategies resulted in both attractive cost-effectiveness and clinical 
effectiveness (2010). The three relevant strategies resulted in an incremental cost-
effectiveness ratio of around $10,500 or less (Kahn et al., 2010).  
Cost-Effectiveness of Diabetes-Related Appointments 
Another study compared the cost-effectiveness of a 6-month monitoring scheme 
to that of a 3-month monitoring scheme through primary care providers for stable type 2 
diabetes patients (Wermeling et al., 2014). The researchers looked at 2,215 patients 
between the ages of 40 and 80 years of age under the care of 233 general practitioners 
across the Netherlands (Wermeling et al., 2014). To be eligible, the patients could not be 
on insulin treatment, had to be in a stable condition (defined as HbA1c ≤7.5%, blood 
pressure ≤145 mmHg, and total cholesterol ≤201 mg/dL), and had to have a type 2 
diabetes diagnoses for at least a year (Wermeling et al., 2014). Finally, the patients 
selected did not have a strong preference for which treatment group they joined and were 
randomized (Wermeling et al., 2014). At the 18-month follow-up period, Wermeling et 
al. then assessed the percentage of patients with a stable condition as previously defined 
(2014).  
Surprisingly, the percentage of patients who met the criteria for a stable condition 
at the 18-month follow-up was 69.5% for the 3-month group to 69.8% for the 6-month 
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group (Wermeling et al., 2014). This meant that the 6-month group actually had 
marginally better outcomes under this criteria compared the 3-month group even though 
they were seen half as many times by the general practitioner (Wermeling et al., 2014). 
Given that 6-month monitoring scheme was €387 (~$580) cheaper than the 3-month 
monitoring scheme, these results demonstrate that the 6-month monitoring scheme was 
cost saving (better outcomes and lower costs) compared to the 3-month monitoring 
scheme (Wermeling et al., 2014). It should be noted, however, that the 95% confidence 
interval for the difference in outcomes between the two groups indicates there is 
significant ambiguity in what the difference likely is for the real population (95% CI: -6.2 
to 6.7%) (Wermeling et al., 2014).  
Interestingly, Wermling et al. chose not to include a QALY measure in 
determining cost effectiveness, even though they collected that data as well (2014). The 
EQ-5D—a quality-of-life measure—indicates that the follow-up EQ-5D for the 3-month 
group was the same as the baseline EQ-5D for the 3-month group (the mean for both was 
0.87 with different standard deviations for each) (Wermeling et al., 2014). For the 6-
month group the follow-up EQ-5D was also the same the baseline EQ-5D (the mean for 
both was 0.86 with different standard deviations for each) (Wermeling et al., 2014). 
Given the short frame of the study, the long-term quality of life and life expectancy could 
not be determined for the two treatment groups (Wermeling et al., 2014). In any case, the 
results at least indicate that the outcomes between the 3-month and 6-month groups are 
comparable, so patients who remain stable at an appointment could reasonably schedule 
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their next appointment 6 months later without any noticeable difference in outcomes 
compared to scheduling their next appointment 3 months later (Wermeling et al., 2014).  
Cost-Effectiveness of Established Diabetes Therapies 
Herman et al. published a seminal study on the cost-effectiveness of lifestyle 
modification and metformin therapy following diabetes diagnosis by using lifetime costs 
for their calculations (2005). The target population included patients 25 years or older 
collected from the Diabetes Prevention Program data set (Herman et al., 2005). The study 
included the health system and the societal perspectives (Herman et al., 2005). The 
results are shown in Table 2 (Herman et al., 2005).  
Table 2: Sensitivity analyses of lifestyle intervention and metformin intervention. 
The cost-effectiveness of lifestyle modification and metformin are assessed in relation to 
the placebo intervention. Adapted from Herman et al., 2005. 
 
 
As shown in Table 2, Herman et al. establish the base-case cost-effectiveness of 
lifestyle modification (through the Diabetes Prevention Program) and metformin therapy 
as $1,124/QALY and $31,286/QALY, respectively, in comparison to the placebo 
intervention (2005). For adults age 55-64, the cost-effectiveness of lifestyle modification 
and metformin therapy are $3,409/QALY and $64,904/QALY, respectively (Herman et 
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al., 2005). Lifestyle modification was by far the most cost-effectiveness intervention 
under any set of assumptions (Herman et al., 2005); in many cases, lifestyle modification 
even produced costs savings, especially for the 25-44 year age group under the base-case 
analysis (Herman et al., 2005). Lifestyle modification was estimated to prolong the type 2 
diabetes incidence by 11 years compared to 3 years for metformin (Herman et al., 2005). 
Finally, lifestyle modification and metformin decreased the incidence of diabetes and the 
incidence of any diabetes-related complications with lifestyle modification again arising 
as the more effective of the two (Herman et al., 2005). The results from this well-cited 
study likely solidified lifestyle modification and metformin therapy as the predominant 
treatments for type 2 diabetes as seen today.   
Cost-Effectiveness of Insulin Analogues 
 Oral glucose-lowering drugs (OGLDs) are not always effective in controlling 
blood glucose levels alone, so an insulin therapeutic must be added to help bring blood 
glucose levels back to an acceptable range (Home et al., 2014). The administration of 
insulin analogues is one amongst various strategies to manage diabetes mellitus 
(Cameron & Bennett, 2009). Endogenous insulin secretion includes both bolus and basal 
components that insulin analogues try to replicate (Cameron & Bennett, 2009). Thus, 
there are rapid-acting analogues designed to satisfy bolus demands (around mealtime) 
and long-acting analogues for maintaining basal insulinization (Cameron & Bennett, 
2009). Cameron and Bennett found that the use of these insulin analogues correlates with 
a decrease in diabetes-related complications and a greater number of QALYs compared 
to conventional insulin therapy (2009); however, the researchers also found that costs 
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associated with using insulin analogues are significantly greater than the costs associated 
with recombinant DNA human insulin therapy (Cameron & Bennett, 2009). Cameron and 
Bennett determined that the use of insulin analogues are only necessary for patients with 
a high risk of entering a hypoglycemic state, and thus, the mass administration of insulin 
analogues would not be prudent for the all diabetics (2009).  
Home et al. decided to use the results of the A1chieve study in their own cost 
effectiveness analysis to examine whether a treatment protocol consisting of OGLDs and 
insulin is not only more effective but more cost-effective than a treatment protocol of 
only OGLDs in patients with type 2 diabetes (2014). The A1chieve study was an 
observational/non-interventional cohort study that followed 44,872 insulin-naïve and 
21,854 insulin-experienced patients with type 2 diabetes beginning insulin aspart 30, 
insulin detemir, or biphasic insulin aspart over the course of 24 weeks (Home et al., 
2014).  
For the purposes of their study, Home et al. studied populations who were 
beginning insulin detemir in Mexico (n=109), India (n=487), Indonesia (n=109), India 
(n=1491), and Algeria (n=473) (2014). In addition, individuals who had HbA1C 
measurements both at baseline and 24 weeks after receiving insulin detemir therapy were 
included in the study (Home et al., 2014). The authors then used a discount rate of 3.0% 
throughout the 24-week period (Home et al., 2014). To examine the health outcomes, 
Home et al. utilized EQ-5D HRQoL measures assessed at baseline and at 24 weeks 
(Home et al., 2014). The authors then projected the financial and clinical consequences of 
adding insulin detemir to the treatment regimen compared to just taking OGLDs for each 
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of the countries over 30 years (Home et al., 2014). Finally, the authors also utilized the 
IMS Centre for Outcomes Research (CORE) Diabetes Model—constructed using a 
arrangement of Markov models—to establish the long-term health outcomes and costs 
associated with beginning insulin detemir for people who are not able to achieve 
appropriate blood glucose levels on OGLDs alone (Home et al., 2014). This includes the 
costs of a wide range of complications, such as cardiovascular disease, eye disease, and 
hypoglycemia to name a few (Home et al., 2014). The CORE Diabetes Model utilized 
Monte Carlo simulations to estimate the probabilities of developing these complications 
(Home et al., 2014).  
 By beginning insulin detemir in addition to these OGLD treatments, subjects in 
the five countries all experienced an increase in life expectancy in the 30-year base case: 
Mexico (1.9 years), India (1.6 years), Algeria (0.8 years), Indonesia (1.0 year), and South 
Korea (1.0 year) (Home et al., 2014). In addition, beginning insulin detemir was also 
associated with decreased incidence of diabetes-related complications in comparison to 
taking OGLDs alone: 25% to 38% for vision loss, 48% to 68% for late-stage renal 
disease, 2% to 17% for foot ulcers, and 12% to 22% for myocardial infarction (Home et 
al., 2014). Overall, the QALY improvements were as follows: Algeria (1.2), India (5.0), 
Mexico (2.5), Indonesia (1.8), and South Korea (1.0) (Home et al., 2014). The additional 
cost of taking insulin detemir in addition to OGLDs was anywhere between two and five 
times greater than taking OGLDs alone (Home et al., 2014). The authors decided to also 
express the numerator of their incremental cost effectiveness ratios (ICERs) in terms of 
their fraction of GDP per capita (Home et al., 2014). It seemed this approach was meant 
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to account for differences in purchasing power amongst people of these different 
countries (Home et al., 2014). The results of the study are shown in Table 3 (Home et al., 
2014). 
Table 3: Short-term and long-term cost effectiveness of adding insulin detemir to 
OGLDs as a treatment protocol for those unresponsive to OGLDs. The 1-year and 
30-year ICER calculations are shown as costs per patient. Adapted from Home et al., 
2014. 
 
 
 As shown in Table 3, the cost effectiveness of these treatments varied 
significantly across the five countries for both the 30-year ICER and 1-year ICER 
calculations (Home et al., 2014). The following are the 30-year ICER calculations for 
these five countries: Mexico (-0.02), South Korea (0.00), Indonesia (0.12), India (0.48), 
and Algeria (0.88) (Home et al., 2014). In addition, the following are the 1-year ICER 
calculations for these five countries: Mexico (0.15), South Korea (0.06), Indonesia (0.68), 
India (0.71), and Algeria (1.48) (Home et al., 2014).  
As one can see, the addition of insulin detemir to the treatment regimen of those 
who are unresponsive to OGLDs is a cost saving approach in the 30-year calculation 
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since incremental costs are lower and incremental QALYs are increasing (Home et al., 
2014). For South Korea, the addition of insulin detemir is nearly insignificant to 
incremental costs in USDs and as a fraction of GDP (Home et al., 2014); therefore, ICER 
as a fraction of GDP is 0.00 to indicate the low incremental cost of medication coupled 
with significant increases in QALYs (Home et al., 2014). It is important to note that 
while the ICER calculations for both the 1-year and 30-year periods in terms of USDs 
never exceeded $10,000/QALY, the cost of medications in Algeria and India were 
significantly higher in real terms (Home et al., 2014). The average Indian patient who 
was unresponsive to OGLDs, for example, would have to pay 48% of his income (with 
the assumption that GDP per capita roughly translates to income per capita) to achieve 
one more QALY, even though this number is only $707/QALY in USD terms (Home et 
al., 2014). In Algeria, the 30-year ICER was $4,625/QALY in terms of USDs and 
0.88/QALY in terms of GDP fraction, which were the highest of any of the countries in 
both (Home et al., 2014). Overall, Home et al. deemed the addition of insulin detemir to 
the treatment regimen to be cost-effective (2014). Given the short window of the 1-year 
ICER, it is likely not worth discussing the practical implications of these calculations.  
 In another study, Zhang et al. sought to assess the cost effectiveness of adding 
additional medications as second-line therapies to the standard metformin and insulin 
regimen for treating diabetes mellitus from the patient perspective (2014). A total of four 
treatments arms were studied: metformin, sulfonylurea, and insulin (T1); metformin, 
DPP-4 inhibitor, and insulin (T2); metformin, GLP-1 agonist, and insulin (T3); 
metformin and insulin (T4) (Zhang et al., 2014). The patients began metformin 
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monotherapy once the target HbA1c level had been reached (Zhang et al., 2014). 
Following that point, other agents (DPP-4 inhibitors, GLP-1 analogs, and sulfonylureas) 
were added to the treatment protocol as shown in T1-T3 if the HbA1c target was ever 
exceeded, and insulin was added to the treatment regimen as a tertiary line of therapy if 
patients still exceeded their HbA1c target first-line and second-line therapies alone 
(Zhang et al., 2014). 
 The authors then classified ten Markov states in their Markov model based on the 
specific HbA1c level corresponding to one of ten tiers (Zhang et al., 2014). The period of 
each cycle in their model was 3 months, and the authors used an annual discount rate of 
3% (Zhang et al., 2014). To gather patient data, the authors used the claims data and 
clinical data from a large U.S. health plan that services patients across the country (Zhang 
et al., 2014). By the end of their selective process for identifying patients who met their 
criteria, Zhang et al. had 37,501 patients who were all at least 40 years of age and 
received their type 2 diabetes diagnosis between 1995 and 2010 (2014). The base-case 
results of the four treatment regimens are shown in Table 4 for both women and men 
when glycemic control goal was ignored (Zhang et al., 2014). It is important to note that 
these are listed as simple cost effectiveness ratios (not incremental cost effectiveness 
ratios) (Zhang et al., 2014).  
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Table 4: Base-case results of the four treatment arms. The base-case results, including 
expected life years, expected QALYs, expected medication cost (USD) per QALY, and 
mean time to use insulin (years), are shown for the four treatments arms. The expected 
medication cost (USD) per QALY is a simple cost effectiveness ratio. Adapted from 
Zhang et al., 2014. 
 
 
As shown in Table 4, the expected QALYs of all four treatments are very similar 
amongst men and women, but the differences in expected medication cost (USD) per 
QALY are more discernable (Zhang et al., 2014). For men, the simple cost effectiveness 
ratios were as follows in decreasing order: T3 ($2,791/QALY), T4 ($2,750/QALY), T2 
($2,741/QALY), and T1 ($2,600/QALY) (Zhang et al., 2014). For women, the simple 
cost effectiveness ratios were as follows in decreasing order: T3 ($2,891/QALY), T4 
($2,845/QALY), T2 ($2,835/QALY), and T1 ($2,675/QALY) (Zhang et al., 2014). For 
both men and women, T1—metformin, sulfonylurea, and insulin—seemed to provide the 
best value for patients in terms of expected cost of medication per QALY, whereas T3—
metformin, GLP-1 agonist, and insulin—seemed to provide the worst value for patients in 
terms of expected cost of medication per QALY (Zhang et al., 2014).  
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Also of importance is the fact that T1 allowed both men and women to remain 
insulin independent for the longest mean period of time (2.76 years for men; 2.59 years 
for women) compared to the other treatment groups (Zhang et al., 2014). Remaining 
insulin independence for as long as possible is likely a significant consideration to the 
patient for the sake of convenience if nothing else. The results are more nuanced when 
visualized with blood glucose level targets (Zhang et al., 2014). In Figure 7, one can see 
the simple cost effectiveness ratios of the four treatment regimens for men and women 
divided into three HbA1c targets (6.5%, 7.0%, and 8.0%) (Zhang et al., 2014).  
 
Figure 7: Cost effectiveness ratios for the four treatment arms divided into three 
HbA1c targets. The x-axis shows the expected medication cost per QALY, whereas the 
y-axis shows the expected QALYs prior to the first event (i.e., a diabetes-related 
complication or death). Adapted from Zhang et al., 2014. 
 
 The results in Figure 7 provide a more personalized approach to deciding which 
of the four treatment regimens is best suited for the given HbA1c target (Zhang et al., 
2014). As one can see, T1—metformin, sulfonylurea, and insulin—still has the most 
desirable expected medication cost per QALY and expected QALYs prior to the first 
event in men and women and amongst all three HbA1c targets (Zhang et al., 2014). The 
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effectiveness (given as expected QALYs prior to the first event) of T1 was superior to 
that of other treatment arms for the 6.5% and 7% HbA1c targets but fell just short of the 
effectiveness of T2 (metformin, DPP-IV, and insulin) for the HbA1c target of 8.0% 
(Zhang et al., 2014).  The difference at the 8.0% HbA1c target is likely statistically 
insignificant, and the cost-effectiveness of T1 is still significantly more attractive 
compared to T2 (Zhang et al., 2014). Overall, T1 was not only the most cost effective 
approach in terms of $/QALYs but also the most effective approach in terms of expected 
QALYs prior to the first event (with the exception of the 8% HbA1c target for the latter) 
(Zhang et al., 2014). Therefore, implementation of sulfonylurea in a patient’s treatment 
regimen as a second-line therapy should appeal to all parties (clinicians, patients, and 
payers) for the 6.5% HbA1c and 7% HbA1c targets at the very least (Zhang et al., 2014). 
Sensitivity analyses in comparison to the base case assumptions—given later in the 
study—also confirm this overall trend (Zhang et al., 2014).  
 Bariatric surgery for severely obese type 2 diabetics is also an important 
consideration for clinicians in improving the life expectancy and quality of life for that 
subpopulation of type 2 diabetic patients (Hoerger et al., 2010). Heorger et al. expanded 
on the Centers for Disease Control and Prevention-RTI Diabetes Cost-Effectiveness 
Model to assess the cost-effectiveness of performing bariatric surgery on severely obese 
patients (defined as BMI ≥35 kg/m2) (2010). The authors believed that bariatric surgery 
could lead to diabetes remission and an overall improvement in the quality of life for 
these patients by reducing the incidence of diabetes-related complications (Hoerger et al., 
2010). In their simulation, Hoerger et al. estimated the costs, QALYs, and cost-
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effectiveness of both gastric bypass surgery and gastric banding surgery with respect to 
traditional diabetes patient care (2010). All costs were expressed as 2005 U.S. dollars 
under the medical-care component of the Consumer Price Index, and both costs and 
QALYs were discounted by 3% (Hoerger et al., 2010). The results of the cost-
effectiveness analysis are shown in Table 5 (Hoerger et al., 2010).  
Table 5: Cost effectiveness ratios bypass surgery and banding surgery. The cost 
effectiveness of bypass surgery and banding surgery are compared to the control of no 
surgery (the current standard of care). The table separates the estimates for patients with a 
new diabetes diagnosis from those with an already established diabetes diagnosis. 
Adapted from Hoerger et al., 2010. 
 
 As shown in Table 5, the QALYs for no surgery, bypass surgery, and banding 
surgery were 9.55 QALYs, 11.76 QALYs, and 11.12 QALYs, respectively, for patients 
with a new diagnosis of diabetes (Hoerger et al., 2010). The total costs for no surgery, 
bypass surgery, and banding surgery were $71,130, $86,665, and $89,029, respectively, 
for patients with a new diagnosis of diabetes (Hoerger et al., 2010). Using these numbers, 
the incremental cost-effectiveness ratio of bypass surgery and banding surgery for 
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patients with an established diabetes diagnosis were determined to be $7,000/QALY and 
$11,000/QALY, respectively (Hoerger et al., 2010). Given that they are both compared to 
the standard of care (no surgery), one can infer that bypass surgery is both a more cost-
effective and effective strategy than banding surgery for patients with a new diabetes 
diagnosis and a BMI greater than or equal to 35 kg/m2 because it results in lower costs 
and better outcomes (Hoerger et al., 2010).  
 The relative cost-effectiveness of bariatric surgery compared to banding surgery is 
roughly similar for patients with an already established diabetes diagnosis (Hoerger et al., 
2010). As shown in Table 5, the QALYs for no surgery, bypass surgery, and banding 
surgery were 7.68 QALYs, 9.38 QALYs, and 9.02 QALYs, respectively, for patients 
with an established diabetes diagnosis (Hoerger et al., 2010). The total costs for no 
surgery, bypass surgery, and banding surgery were $79,618, $99,944, and $96,921, 
respectively, for patients with an established diabetes diagnosis (Hoerger et al., 2010). 
Using these numbers, the incremental cost-effectiveness ratio of bypass surgery and 
banding surgery for patients with an established diabetes diagnosis were determined to be 
$12,000/QALY and $13,000/QALY, respectively (Hoerger et al., 2010). Given that they 
are both compared to the standard of care (no surgery), one can infer that bypass surgery 
is both a more cost-effective and effective strategy than banding surgery for patients with 
an established diabetes diagnosis and a BMI greater than or equal to 35 kg/m2 because it 
results in lower costs and better outcomes (Hoerger et al., 2010).  
Therefore, regardless of whether the patient has a newly established diabetes 
diagnosis or a previously established diabetes diagnosis, a patient with a BMI greater 
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than or equal to 35 kg/m2 should always be considered for bariatric surgery after 
evaluating the patient’s individual risk factors for surgical complications (Hoerger et al., 
2010). Sensitivity analyses provided by Hoerger et al. indicate that under any set of 
assumptions the cost-effectiveness of bariatric surgery and banding surgery is always 
under $40,000/QALY in comparison to the current standard of care (no surgery) (2010). 
The authors also list some of the perceived limitations of the study: selection of health 
parameters, limited data on long-term effects of bariatric surgery, assumption of quality 
of life improvement based on BMI decrease based on cross-sectional data, poor data on 
diabetes remission, limited data on surgical outcomes for patients with established 
diabetes diagnoses, and homogenous diabetes progressions rates based on HbA1c levels 
for both obese and non obese persons (Hoerger et al., 2010).  	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RESULTS 	   	  	  
The main findings of the six studies reported are as follows: 1) lifestyle 
modification is the most cost-effective intervention for treating DM at any age and under 
any set of assumptions compared to metformin and the placebo intervention and could be 
cost saving for adults between the age of 25 to 44 (Herman et al., 2005), 2) screening for 
DM beginning at age 30 or 45 and continued every 3 or 5 years thereafter is 
acknowledged as a cost-effective (≤$10,500/QALY) (Kahn et al., 2010), 3) scheduling a 
six-month follow-up appointment with a primary care provider is more cost-effective 
than scheduling a three-month follow-up appoint for stable diabetics (HbA1c ≤7.5%, 
blood pressure ≤145 mmHg, and total cholesterol ≤201 mg/dL) (Wermeling et al., 2014)., 
4) metformin has proven its cost-utility as a first-line therapy (i.e., the default option for a 
patient diagnosed with DM) (Herman et al., 2005), 5) sulfonylurea is a significantly 
better second-line therapy compared to DPP-4 inhibitors and GLP-1 analogs (Zhang et 
al., 2014), 6) insulin detemir, even though it has a desirable cost effectiveness overall, has 
variable cost effectiveness across countries in terms of both nominal and purchasing 
power terms (Home et al., 2014), 7) bariatric surgery for patients with a previously 
established or newly established diabetes diagnosis and a BMI greater than or equal to 35 
kg/m2 is more cost-effective when compared to both banding surgery and no intervention 
(Hoerger et al., 2010). Combining these findings could help establish a cost-effective 
standard of care for the long-term management of diabetes mellitus for all patients.   
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DISCUSSION 
 	   The key to establishing a cost-effective standard of care that satisfies healthcare 
providers who always strive to provide the best quality care and healthcare managers who 
are focused on controlling costs is finding a balance between cost-effectiveness and 
clinical effectiveness. A screening test that is repeated every day, for example, might 
result in maximal effectiveness (i.e., highest expected number of QALYs out of any other 
screening strategies), but it would be impractical and costly to conduct a screening test 
every single day, especially if there were no statistically significant benefit compared to 
testing every year. Therefore, through input from both clinicians and health economists, 
an ethical, practical approach that balances cost effectiveness and clinical effectiveness 
should be devised.   
 In addition, following an established protocol could allow primary care providers 
to exclusively manage stable prediabetic and early stage DM patients with no diabetes-
related complications, allowing endocrinologists to focus on managing DM patients who 
are not responsive to the established protocols or have diabetes-related complications that 
require specialized attention. For all patients, the primary care provider should reinforce 
the importance of lifestyle modification (including diet and exercise) in preventing 
debilitating chronic diseases later in life (Herman et al., 2005). As previously noted, this 
preventative strategy would produce cost savings if initiated earlier in life (Herman et al., 
2005). The PCP should also screen patients for diabetes beginning at age 30 and repeat 
screening every three years thereafter unless a diabetes diagnosis has been established 
(Kahn et al., 2010). The cost-effectiveness of screening at age 30 and repeating testing 
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every three years is comparable to that of screening at age 45 and repeating testing every 
three years or five years in terms of $/QALYs (Kahn et al., 2010); however, the clinical 
effectiveness of beginning screening at 30 and repeating every three years is markedly 
greater than those of the other two strategies previously mentioned (Kahn et al., 2010). 
Therefore, a primary care provider would be most comfortable with screening at age 30 
and repeating every three years to ensure both cost considerations and effectiveness 
considerations are balanced in the joint interest of the patient and society.  
Upon reaching a diagnosis of DM, the clinician should initially prescribe 
metformin to the patient given its proven effectiveness in numerous clinical trials as a 
first-line therapy for the treatment of DM and its proven cost effectiveness amongst 
health economists (Herman et al., 2005). The primary care provider should then check the 
patient’s BMI to see if it is greater than or equal to 35 kg/m2 (Hoerger et al., 2010); if the 
patient’s BMI exceeds this threshold, the primary care provider should recommend the 
patient for bariatric surgery after reviewing the patient’s individual risk factors for this 
type of surgery (Hoerger et al., 2010). Upon assessing the stability of the patient’s 
condition (HbA1c ≤7.5%, blood pressure ≤145 mmHg, and total cholesterol ≤201 
mg/dL), the primary care provider can decide whether to schedule the next follow-up 
appointment three months or six months from that date (Wermeling et al., 2014). A 
primary care provider could be reasonably confident that a diabetic patient assessed as 
stable could be seen again in six months as opposed to three months with no significant 
deterioration in the patient’s condition over that time period, whereas an unstable diabetic 
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patient or a patient changing his or her diabetes treatment regimen would require a 
follow-up appointment in 3 months (Wermeling et al., 2014).  
At the next follow-up appointment, the primary care provider should once again 
assess the stability of the patient’s condition. If the patient is not meeting a set HbA1c 
target from 6.5% to 8% with metformin alone, the primary care provider should consider 
adding a sulfonylurea to the patient’s treatment along with the existing metformin 
prescription (Zhang et al., 2014). As previously noted, however, the primary care 
provider will have to be cautious of the increased risk of cardiac events and weight gain 
observed with sulfonylurea medications (Kaiser & Oetjen, 2014). At the next visit, if the 
patient still fails to show response to metformin and sulfonylurea treatments in reaching 
the HbA1c target, insulin therapy, such as insulin detemir, should be utilized in the 
patient’s treatment regimen to help the patient reach the HbA1c target (Zhang et al., 
2014; Home et al., 2014). Once the patient has achieved the HbA1c target and the 
patient’s overall condition is stable, the primary care provider can then see the patient 
every six months thereafter to monitor the stability of the patient’s DM condition and 
overall health. If at any point the patient requests more personalized care or if the primary 
care provider believes a standardized treatment protocol would be ineffective for the 
specific case, the primary care provider should refer the patient to an endocrinologist. 
 In summary, the treatment protocol is as follows: 
1. Always emphasize the importance of lifestyle modification (including diet and 
exercise) to all patients regardless of age. (Herman et al., 2005) 
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2. Screen for diabetes mellitus every 3 years starting at age 30 unless a diabetes 
diagnosis is established. (Kahn et al., 2010) 
3. After a diabetes diagnosis has been established, prescribe metformin and set an 
achievable HbA1c target for the patient. (Herman et al., 2005; Zhang et al., 2014) 
4. Consider recommending the patient for bariatric surgery if the patient’s BMI is 
greater than or equal to 35 kg/m2. (Hoerger et al., 2010) 
5. Assess the stability of the patient’s condition (HbA1c ≤7.5%, blood pressure ≤145 
mmHg, and total cholesterol ≤201 mg/dL). (Wermeling et al., 2014) 
6. Schedule a follow-up appointment 3-months later to reassess the stability of the 
patient’s condition and the patient’s progress in achieving the HbA1c target. 
(Wermeling et al., 2014) 
7. If the patient has been responding to the metformin therapy, schedule a follow-up 
every 6 months unless the patient’s condition becomes unstable (in which case the 
patient should be seen every 3 months until a stable condition is achieved). If the 
patient is not responding to the metformin therapy alone, add a sulfonylurea to the 
patient’s treatment regimen and schedule a follow-up appointment in 3 months. 
(Wermeling et al., 2014; Zhang et al., 2014) 
8. If the patient has been responding to the metformin and sulfonylurea therapy, 
schedule a follow-up every 6 months unless the patient’s condition becomes 
unstable (in which case the patient should be seen every 3 months until a stable 
condition is achieved). If at the follow-up appointment, a patient currently taking 
metformin and sulfonylurea is still not responding to those treatments in reaching 
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the set HbA1c target, add insulin therapy to the patient’s treatment regimen and 
schedule a follow-up appointment in 3 months. (Home et al., 2014; Wermeling et 
al., 2014; Zhang et al., 2014) 
9. If the patient has been responding to the metformin, sulfonylurea, and insulin 
therapies, schedule a follow-up every 6 months unless the patient’s condition 
becomes unstable (in which case the patient should be seen every 3 months until a 
stable condition is achieved). If at the follow-up appointment, a patient currently 
taking metformin, sulfonylurea, and insulin is still not responding to those 
treatments in reaching the set HbA1c target, assess the patient’s compliance to the 
treatment regimen and refer the patient to an endocrinologist to explore other 
ways to manage their specific diabetes mellitus condition. (Home et al., 2014; 
Wermeling et al., 2014; Zhang et al., 2014) 
Future studies on cost effectiveness analysis should focus on analyzing more 
combinations of established and new antidiabetic drug treatments, including both insulin 
and noninsulin varieties. Comparative effectiveness studies are also important to consider 
in tandem with cost effectiveness studies because proposed interventions that have the 
highest comparative effectiveness and the most desirable cost effectiveness are attractive 
to all parties, including clinicians, payers, and patients. It is important to continue 
conducting cost effectiveness (and comparative effectiveness) studies as new treatments 
enter the market for the treatment of diabetes mellitus because the paradigm of the 
treatment regimen that balances clinical effectiveness and cost effectiveness is naturally 
going to be in flux. 	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